Navigation Links
Newest Coated Stent Does Well in Real-World Trial
Date:6/17/2009

Safe and effective in an 'all-comer population,' researchers say

WEDNESDAY, June 17 (HealthDay News) -- The newest drug-coated stent has performed well in a real-life trial, Dutch cardiologists report.

The Xience stent -- a flexible metal-mesh tube coated with the drug everolimus -- is inserted to keep blood flowing after artery-opening procedures such as angioplasty, and is already in widespread use. It was approved by the U.S. Food and Drug Administration last July, on the basis of good results in controlled trials.

But those trials included only people with simple artery blockages and the effectiveness of the new stent in "complex, unselected patients treated in daily practice still remains unknown and cannot be extrapolated from these randomized controlled trials," said cardiologists at Erasmus Medical Center in Rotterdam in their report, which was released online June 17 in advance of publication in the Journal of the American College of Cardiology. "We therefore sought to evaluate the impact of this second-generation drug-eluting stent on the clinical outcomes in consecutive patients treated in a real-life, all-comer population."

The trial compared the outcomes of 649 people given Xience stents with individuals who previously had stents implanted -- 450 with bare-metal stents, 508 with stents coated with the drug sirolimus and 576 with stents coated with the drug paclitaxel. The data include people with multiple artery blockages and some treated after heart attacks.

In the cautious phrasing of the Rotterdam group, "this study suggests that the use of everolimus-eluting stents in an unselected population may be as safe as and more effective than bare-metal stents, may be as safe and effective as sirolimus-eluting stents, may be as safe as paclitaxel-eluting stents, and may be more effective than paclitaxel-eluting stents."

Specifically, in a six-month follow-up period, the incidence of death, heart attack and stenosis (new blockage of the artery) was lower for the Xience group than for those with bare-metal stents and slightly better than those with first-generation drug-eluting stents.

This is good news, said Dr. Gregg W. Stone, an interventional cardiologist who is a professor of medicine at Columbia University and who took part in the controlled trials that led to FDA approval of Xience.

"This more real-world experience is reassuring," Stone said. But additional studies are needed because "the patient size in this trial was small, and it is more difficult to draw conclusions from non-randomized trials," Stone explained.

Nevertheless, the American cardiology community appears to have drawn its own conclusions already, Stone said. Drug-coated stents now are used in about 75 percent of cases, and the Xience stent is used in "50 to 60 percent of that 75 percent," he said.

Everolimus is a more potent drug than those used in the first-generation coated stents and also is contained in a thin, inert polymer that is less likely to cause inflammation, Stone said. The Xience stent itself is also thinner than the previous devices, he added.

"This is a good step forward on evaluating the next generation of drug-eluting stents," said Dr. Manesh Patel, director of the catheterization research laboratory at Duke University.

"The data I see from the [new study] is reassuring," Patel said. "If you are a patient who is being evaluated and a stent is being considered for your coronary, this stent looks safe for at least six months."

Longer follow-up data on more recipients is needed, he noted. Abbott Vascular, which markets the Xience V stent, is sponsoring a data bank that already has information on 5,000 recipients, Patel said.

Stent research and development continues, Stone stated. A stent with a bioabsorbable polymer that disappears is being tested, and further down the road is a stent that itself would dissolve over time, he said.

More information

The why and how of stents are explained by the U.S. National Library of Medicine.



SOURCES: Gregg W. Stone, M.D., professor, medicine, Columbia University, New York City; Manesh Patel, M.D., associate professor, medicine, Duke University, Durham, N.C.; June 17, 2009, Journal of the American College of Cardiology, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making
2. Carefxs Newest White Paper Illuminates Healthcare CIOs Growing Role in Operations, Strategic Thinking and IT Project Decision Making
3. GNAX/AtlantaNAP Announces Newest Client, Health Information Designs
4. German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAKs CRO Connect Program(TM)
5. L.A.s Newest Advanced Imaging Center Houses New GE 64-Slice PET/CT and 3T MRI in Spa-Inspired Environment
6. Stratus Technologies Signs Allen Technologies as Newest Channel Partner for High Availability Avance Software
7. SafetyTies Keep Getting Safer: Newest Neckties Reduce the Spread of Germs and Stylishly Feature the Microbes They Fight
8. Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast
9. ALDO Supports World AIDS Day by Donating 100% of Proceeds for Newest ALDO Fights Aids Product
10. MedVantx(R) Names Newest Board Member
11. Mens Health Network Welcomes its Newest Member to its Nationwide Team, The Sean Kimerling Testicular Cancer Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newest Coated Stent Does Well in Real-World Trial
(Date:3/1/2017)... NJ (PRWEB) , ... March 01, 2017 , ... ... Annual Miami Lung Cancer Conference® on April 8, 2017, in Sunny Isles Beach, ... chief executive officer, Massachusetts General Physicians Organization, Boston, and Dr. Heather Wakelee, associate ...
(Date:3/1/2017)... ... March 01, 2017 , ... RJ Young, the third largest independent ... Delchamps to Director of Integrated Solution Sales. Harris has been with RJ Young for ... , Harris will lead sales for the IT Services and Software divisions. He will ...
(Date:3/1/2017)... Colorado (PRWEB) , ... March 01, 2017 , ... ... announced the addition of Kara Richardson Whitely as a National Binge Eating Recovery Advocate. ... a highly skilled group of experts in their fields who speak at and attend ...
(Date:3/1/2017)... ... ... Financial Recovery Group, Inc. (FRG), is proud to announce it will participate as ... also is offering a special discount for those who attend the event as a ... brightest minds in the healthcare industry to share information on risk adjustment, quality management, ...
(Date:3/1/2017)... ... March 01, 2017 , ... The Industrial Designers Society of America ... raising awareness of the profession of industrial design (ID) and relaunching "What Is ... high school students and counselors; parents; and the greater public. , Share details and ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Acute Myeloid Leukemia Drugs Price Analysis ... the global Acute Myeloid Leukemia market. This research will ... out how the marketed products for Acute Myeloid Leukemia are clinically ...
(Date:2/28/2017)... 2017 Prefilled Syringes Market: Scope and Segmentation ... This report provides a forecast and analysis ... and regional levels. It provides historical data of ... in terms of revenue (US$ Mn) and volume ... along with an outlook on prefilled syringes consumption ...
(Date:2/28/2017)... , Feb. 28, 2017 Summary ... to better understand Seattle Genetics and its partnering interests ... http://www.reportlinker.com/p03605624-summary/view-report.html Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
Breaking Medicine Technology: